Pediatric CIRB Meeting Agenda

May 14, 2020

I. Continuing Review

AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations (Protocol Version Date 12/28/18)

II. Continuing Review

AAML1531, Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome: A COG Groupwide Phase III Study (Protocol Version Date 07/29/19)

III. Continuing Review

ANBL17P1, A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, dinutuximab) (NSC# 764038, IND# 4308) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma (Protocol Version Date 10/24/19)

IV. Continuing Review

ARST1431, A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) (Protocol Version Date 11/19/18)

V. Continuing Review

PBTC-049, A Phase I study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma and CNS tumors harboring MET aberrations. (Protocol Version Date 02/27/20)
VI. New Study - Initial Review

ANBL19P1, A Pilot Study of Dinutuximab in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma (Protocol Version Date 04/09/20)

VII. Potential Unanticipated Problem and Serious and/or Continuing Noncompliance

APEC1621SC, NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice) Screening Protocol (Protocol Version Date 03/11/20)